Dry-powder inhalers in acute asthma

Therapeutic Delivery

Volumn 5, Issue 1, 2014, Pages 69-81

  Selroos, Olof ^a  

^a NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; SALBUTAMOL; TERBUTALINE;

ASTHMA; BRONCHODILATATION; BRONCHODILATING ACTIVITY; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84890952354     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.132     Document Type: Review

References (54)

1. Selroos O, Borgström L, Ingelf J. Use of dry powder inhalers in acute exacerbations of asthma and COPD. Ther. Adv. Respir. Dis. 3(2), 81-91 (2009).
2. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J. Aerosol Med. 9(1), 55-70 (1996).
3. Selroos O, Pietinalho A, Riska H. Delivery devices for asthma medication. Clinical implications of differences in effectiveness. Clin. Immunother. 6(4), 273-299 (1996).
4. Borgstrom L. On the use of dry powder inhalers in situations perceived as constrained. J. Aerosol Med. 14(3), 281-287 (2001).
5. Brocklebank D, Ram F, Wright J et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airway disease; a systematic review of the literature. Health Technol. Assess. 5(26), 1-149 (2001).
6. Newman SP. Dry powder inhalers for optimal drug delivery. Expert Opin. Biol. Ther. 4(1), 23-33 (2004).
7. Crompton GK. Problems patients having using pressurized aerosol inhalers. Eur. J. Respir. Dis. 63(Suppl.), 101-104 (1982).
8. Borgström L, Asking L, Lipniunas P. An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. J. Aerosol Med. 18(3), 304-310 (2005).
9. McNeill RS, Malcolm GD, Rhind Brown W. A comparison of expiratory and inspiratory flow rates in health and in chronic pulmonary disease. Thorax 14(3), 225-231 (1959).
10. Lindmark B. Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma. Ther. Adv. Respir. Dis. 2(5), 279-299 (2008).
11. Broeders ME, Molema J, Hop WC, Vermue NA, Folgering HT. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir. Med. 98(12), 1173-1179 (2004).
12. Roche N, Dessanges JF, Dubus JC. [Dry powder inhalers in extreme clinical situations]. Rev. Mal. Respir. 22(4), 605-613 (2005).
13. Rodrigo GJ, Neffen H, Colodenco FD, Castro-Rodriguez JA. Formoterol for acute asthma in the emergency department: a systematic review with meta-analysis. Ann. Allergy Asthma Immunol. 104(3), 247-252 (2010).
14. Atkins PJ. Dry powder inhalers: an overview. Respir. Care 50(10), 1304-1312 (2005).
15. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®. Respir. Med. 92(8), 1017-1021 (1998).
16. Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler®) showed as rapid an onset of action as salbutamol given by a pMDI. Respir. Med. 94(6), 607-611 (2000).
17. Freedman BJ. Trial of a terbutaline aerosol in the treatment of asthma and a comparison of its effects with those of a salbutamol aerosol. Brit. J. Dis. Chest 66(3), 222-229 (1972).
18. Chuchalin A, Makarova I, Bergqvist P. As-needed formoterol has an improved safety profile compared with as-needed terbutaline in mild intermittent asthma. Eur. Respir. J. 22 (Suppl. 45), 235s, P1571 (2003).
19. Pauwels RA, Sears MR, Campbell M et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur. Respir. J. 22(5), 787-794 (2003).
20. Grunfeld A, Shragge DL, Dent JM, Soliman S, Svensson KJ, Fitzgerald M. Greater bronchodilation from Bricanyl® Turbuhaler® over Bricanyl® pressurized metered dose inhaler in patients with acute asthma in the emergency department. Amer. J. Respir. Crit. Care Med. 153(Suppl. A), 61 (1996).
21. Nana A, Youngchaiyud P, Maranetra N et al. b2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir. Med. 92(2), 167-172 (1998).
22. Phanareth K, Laursen LC. Bricanyl Turbuhaler versus nebuliser in the treatment of patients with acute severe airways obstruction. Eur. Respir J. 14(Suppl. 30), 61s (1999).
23. Malolepszy J, Böszörményi Nagy G, Selroos O, Larsson P, Brander R. Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction. Eur. Respir. J. 18(6), 928-934 (2001).
24. Boonsawat W, Charoenratanakul S, Pothirat C et al. Formoterol (OXIS®) Turbuhaler® as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir. Med. 97(9), 1067-1074 (2003).
25. Balanag VM, Yunus F, Yang PC, Jorup K. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acuteasthma. Pulm. Pharmacol. Ther. 19(2), 139-147 (2006).
26. Rubinfeld AR, Scicchitano R, Hunt A, Thompson PJ, van Nooten A, Selroos O. Formoterol Turbuhaler® as reliever medication in patients with acute asthma. Eur. Respir. J. 27(4), 735-741 (2006).
27. Bateman ED, Fairall L, Lombardi DM, English R. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir. Res. 7, 13 (2006).
28. Najafizadeh K, Sohrab Pour H, Ghadyanee M, Shiehmorteza M, Jamali M, Majdzadeh S. A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma. Emerg. Med. J. 24(5), 317-321 (2007).
29. Springer C, Stahl E, Schachter J, Avital A. Terbutaline given via Turbuhaler and in nebulised form in children with acute asthma. Eur. J. Clin. Res. 8(3), 163-169 (1996).
30. Drblik S, Lapierre G, Thivierge R et al. Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode. Arch. Dis. Child. 88(4), 319-323 (2003).
31. Avila-Castanón L, Casas-Becerra B, del Rio- Navarro BE, Velázquez-Armenta Y, Sienra- Monge JJL. Formoterol vs albuterol administered via Turbuhaler system in the emergency treatment of acute asthma in children. Allergol. Immunopathol. (Madr.) 32(1), 18-20 (2004).
32. Chong Neto HJ, Chong-Silva DC, Marani DM, Kuroda F, Olandosky M, de Noronha L. Different inhaler devices in acute asthma attacks: a randomized, double-blind, placebo-controlled study. J. Pediatr. (Rio J) 81(4), 298-304 (2005).
33. Bussamra MH, Stelmach R, Rodrigues JC, Cukier A. A randomized,comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting. Ann. Allergy Asthma Immunol. 103(3), 248-253 (2009).
34. Tønnesen F, Laursen LC, Ibsen T, Evald T, Ståhl E. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest 105(3), 697-700 (1994).
35. Raimondi AC, Schottlender J, Lombardi D, Molfino NA. Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder. Chest 112(1), 24-28 (1997).
36. Cordova ER, Accinelli RA. Formoterol Turbuhaler vs salbuterol MDI in adults with acute asthma in the emergency room. Amer. J. Respir. Crit. Care Med. 169(Suppl. A), 313 (2004).
37. Lee-Wong M, Chou V, Ogawa Y. Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. Ann. Allergy Asthma Immunol. 100(2), 146-152 (2008).
38. Chew KS, Kamarudin H, Hashim CW. A randomized open-label trial on the use of budesonide/formoterol (Symbicort®) as an alternative reliever medication for mild to moderate asthmatic attacks. Int. J. Emerg. Med. 5,16 (2012).
39. Rufin P, Benoist MR, Panqueva P, Brouard JJ, de Blic J, Scheinmann P. Efficacité d'un inhalateur de poudre (Turbuhaler) dans la crise d'asthme modérée de l'enfant. Rev. Mal. Respir. 10(6), 545-550 (1993).
40. Solé D, Rizzo MC, Pimentel AF. [Effect of inhaled terbutaline sulphate (dry powder, Turbuhaler and nebulizer solution) in children with acute asthma.] J. Pediatr. (Rio J) 71(2), 82-87 (1995).
41. Lodha R, Gupta G, Baruah BP, Nagpal R, Kabra SK. Metered dose inhaler with spacer versus dry powder inhaler for delivery of salbutamol in acute exacerbations of asthma: a randomized controlled trial. Ind. Pediatr. 41(1), 15-20 (2004).
42. Direkwatanachai C, Teeratakulpisarn J, Suntorniohanakul S et al. Comparison of salbutamol efficacy in children - via the metered-dose inhaler (MDI) with Volumatic® spacer and via the dry powder inhaler, Easyhaler®, with the nebulizer - in mild to moderate asthma exacerbation: a multicenter, randomized study. Asian Pacific J. Allergy Immunol. 29(1), 25-33 (2011).
43. Tattersfield AE, Löfdahl CG, Postma DS et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 357(9278), 257-261 (2001).
44. Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhász G. Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir. Med. 96(6), 412-417 (2002).
45. Richter K. Successful use of DPI systems in asthmatic patients - key parameters. Respir. Med. 98(Suppl. B), S22-S27 (2004).
46. Borgström L, O'Callaghan C, Bisgaard H, Pedersen S. Dry-powder inhalers. In: Drug delivery to the lungs. Bisgaard H, O'Callaghan C, Smaldone CC, (Eds). Marcel Dekker, NY, USA, 421-428 (2002).
47. Engel T, Heinig JH, Madsen F, Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur. Respir. J. 3(9), 1037-1041 (1990).
48. Brown P, Ning A, Greening A, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler® in acute asthma. Eur.Respir. J. 8(11), 1940-1941 (1995).
49. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis. Child. 65(3), 308-310 (1990).
50. Lötvall J, O'Byrne P. Targeting drugs to the airways by different inhalation devices. Role of deposition characteristics. BioDrugs 12(4), 279-289 (1999).
51. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am. J. Respir. Crit. Care Med. 153(5), 1636-1640 (1996).
52. Donovan MJ, Gibbons A, Herpin MJ, Marek S, McGill SL, Smyth HD. Novel dry powder inhaler particle-dispersion systems. Ther. Deliv. 2(10), 1295-1311 (2011).
53. Stegemann S, Kopp S, Borchard G et al. Developing and advancing drug powder inhalation towards enhanced therapeutics. Eur. J. Pharm. Sci. 48(1-2), 181-194 (2013).
54. Global Initiative for Asthma. Global strategy for asthma management and prevention - updated 2012. www.ginasthma.com